2005
Should the FDA be the doctor of last resort?
DeVita V. Should the FDA be the doctor of last resort? Nature Reviews Clinical Oncology 2005, 2: 423-423. PMID: 16264991, DOI: 10.1038/ncponc0292.Peer-Reviewed Original Research
1975
Patterns of involvement with malignant lymphoma and implications for treatment decision making.
Johnson R, DeVita V, Kun L, Chabner B, Chretien P, Berard C, Johnson S. Patterns of involvement with malignant lymphoma and implications for treatment decision making. British Journal Of Cancer. Supplement 1975, 2: 237-41. PMID: 1182071, PMCID: PMC2149575.Peer-Reviewed Original ResearchConceptsMalignant lymphomaTreatment decisionsPresentation of lymphomaPrimary extranodal lymphomaMajority of patientsUntreated malignant lymphomaPattern of involvementMajority of casesLymphatic irradiationProspective stagingSurgical stagingExtranodal lymphomaExtranodal sitesHaematogenous spreadSystemic treatmentClinical courseConsecutive patientsLymph nodesDisease extentHodgkin's diseaseDisseminated involvementAppropriate treatmentLymphatic extensionPrimary manifestationHigh dose